联合拷贝数、甲基化标志物和突变经阴道棉条检测子宫内膜癌
该研究在38例子宫内膜癌患者和28例良性指征女性术前收集阴道棉条,提取脱落DNA进行低覆盖全基因组测序、焦磷酸测序和二代测序,评估拷贝数、甲基化标志物和突变单独及联合检测的效率。甲基化特异性最高但敏感性低,突变分析敏感性提高,联合三类标志物任一阳性时敏感性92%、特异性86%。
要点
- 阴道棉条收集脱落DNA可用于子宫内膜癌无创检测的概念验证。
- 甲基化标志物(HOXA9、RASSF1、HTR1B)特异性100%但敏感性37-40%。
- 突变分析敏感性50%、特异性83%,未增加拷贝数联合甲基化的敏感性。
核心结论
- 本研究展示了子宫内膜癌无创且精确检测的概念验证,作者提出改进标志物检测后可能开发有临床价值的检测方法。
研究设计与样本
- 在子宫切除术前从38例子宫内膜癌患者和28例良性指征女性收集阴道棉条,提取DNA进行低覆盖全基因组测序评估拷贝数、焦磷酸测序测量HOXA9、RASSF1和CDH13启动子甲基化百分比、二代测序检测19个与子宫内膜癌相关基因的突变。
主要发现
- 甲基化分析特异性最高但敏感性最低(HOXA9、RASSF1和HTR1B敏感性37-40%,特异性100%),突变分析敏感性提高(敏感性50%,特异性83%)。
- 良性手术指征女性中仅一例拷贝数变异假阳性,该例基于拷贝数变化检测,并与子宫切除时才识别的平滑肌肉瘤相关。
- 将三类生物标志物中任一类阳性视为阳性,敏感性92%、特异性86%。
- 突变分析未增加拷贝数和甲基化联合分析的敏感性。
关键数值与推荐
- 甲基化标志物HOXA9、RASSF1和HTR1B敏感性37-40%,特异性100%。
- 突变分析敏感性50%,特异性83%。
- 三类标志物任一阳性联合检测敏感性92%,特异性86%。
临床怎么用
- 阴道棉条收集脱落DNA联合拷贝数、甲基化和突变分析可能用于子宫内膜癌无创检测,但需改进标志物检测后进一步开发临床可用检测方法。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to assess whether endometrial cancer (EC) can be detected in shed DNA collected with vaginal tampon by analyzing copy number, methylation markers, and mutations. METHODS: Tampons were collected prior to hysterectomy from 38 EC patients and 28 women with benign indications. Extracted tampon DNA underwent the following: 1) low-coverage whole genome sequencing (LC-WGS) to assess copy number, 2) pyrosequencing to measure percent promotor methylation of HOXA9, RASSF1, and CDH13 and 3) next generation sequencing (NGS) to identify mutations in 19 genes associated with EC identified through The Cancer Genome Atlas. Sensitivity and specificity for each test and test combinations were calculated. RESULTS: Methylation analysis yielded the highest specificities but lowest sensitivities (37-40% sensitivity; 100% specificity for HOXA9, RASSF1 and HTR1B) while mutation analysis had improved sensitivity (50% sensitivity; 83% specificity). Only one "false positive" result for copy number variants was identified among women with benign surgical indications, which was based on detection of copy number changes, and associated with a leiomyosarcoma that was only recognized at hysterectomy. Considering any of the 3 biomarker classes as a positive, resulted in a sensitivity of 92% and specificity of 86%. Mutation analysis did not add sensitivity to the combination of analysis of copy number and methylation. CONCLUSIONS: This study demonstrates a proof-of-principle for non-invasive yet precise detection of endometrial cancer. We propose that with improved biomarker testing, it may be possible to develop a clinically useful test for detecting EC.
引用
- Sangtani A, Wang C, Weaver A, et al. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecol Oncol. 2019. PMID: 31787246. doi:10.1016/j.ygyno.2019.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。